Investidores da Novartis voltam os holofotes para fusões e aquisições após reveses em ensaios clínicos https://www.reuters.com/legal/transactional/novartis-investors-turn-spotlight-ma-after-trial-setbacks-2026-09-11/?taid=6aa3b182266066000192ac20 https://www.reuters.com/legal/transactional/novartis-investors-turn-spotlight-ma-after-trial-setbacks-2026-09-11/?taid=6aa3b182266066000192ac20